KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Cash from Financing Activities (2017 - 2025)

Aquestive Therapeutics (AQST) has 8 years of Cash from Financing Activities data on record, last reported at $660000.0 in Q4 2025.

  • For Q4 2025, Cash from Financing Activities rose 320.38% year-over-year to $660000.0; the TTM value through Dec 2025 reached $102.6 million, up 22.76%, while the annual FY2025 figure was $102.6 million, 22.76% up from the prior year.
  • Cash from Financing Activities reached $660000.0 in Q4 2025 per AQST's latest filing, down from $81.4 million in the prior quarter.
  • Across five years, Cash from Financing Activities topped out at $81.7 million in Q1 2024 and bottomed at -$9.2 million in Q1 2023.
  • Average Cash from Financing Activities over 5 years is $11.6 million, with a median of $4.1 million recorded in 2023.
  • Peak YoY movement for Cash from Financing Activities: plummeted 809.17% in 2023, then soared 478988.24% in 2025.
  • A 5-year view of Cash from Financing Activities shows it stood at $5.5 million in 2021, then crashed by 95.71% to $234000.0 in 2022, then surged by 1572.22% to $3.9 million in 2023, then tumbled by 95.99% to $157000.0 in 2024, then surged by 320.38% to $660000.0 in 2025.
  • Per Business Quant database, its latest 3 readings for Cash from Financing Activities were $660000.0 in Q4 2025, $81.4 million in Q3 2025, and -$100000.0 in Q2 2025.